Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Jun 13, 2013
Genomic medicine achieved a major victory as the Supreme Court invalidated the patents held by Myriad Genetics on the BRCA1 and BRCA2 genes, on the grounds that human genes are products of nature and therefore ineligible to be patented.
CAP has long opposed the issuing of gene patents and is a co-plaintiff in the case Association of Molecular Pathology et al, vs Myriad Genetics, Inc., which the court decided June 13, 2013.